URL: http://www.leukemia-net.org/content/e58/e525/e2918/index_eng.html

micronavigation ELN path item Leukemias path item MDS path item Publications  · 
Workpackage 8

Publications



  1. Amadori S, Suciu S, Stasi R, Willemze R, Mandelli F, Selleslag D, Denzlinger C, Muus P, Stauder R, Berneman Z, Pruijt J, Nobile F, Cassibba V, Marie JP, Beeldens F, Baila L, Vignetti M, de Witte T.: Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups.
    Leukemia Oct;19(10):1768-73, 2005
    Subjects: MDS
  2. Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, Muus P, Lefrere F, Berneman Z, Fillet G, Denzlinger C, Willemze R, Leoni P, Leone G, Casini M, Ricciuti F, Vignetti M, Beeldens F, Mandelli F, De Witte T; EORTC/GIMEMA Leukemia Group: Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study.
    Blood 2005 Jul 1;106(1):27-34. Epub 2005 Mar 10
    Subjects: MDS
  3. Barouk-Simonet E, Soenen-Cornu V, Roumier C, Cosson A, Lai JL, Fenaux P, Preudhomme C.: Role of multiplex FISH in identifying chromosome involvement in myelodysplastic syndromes and acute myeloid leukemias with complex karyotypes: a report on 28 cases.
    Cancer Genet Cytogenet 2005 Mar;157(2):118-26
    Subjects: MDS
  4. Bowen DT.: Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients.
    Semin Oncol. 2005 Aug;32(4 Suppl 5):S16-23
    Subjects: MDS
  5. Germing U, Hildebrandt B, Pfeilstocker M, Nosslinger T, Valent P, Fonatsch C, Lubbert M, Haase D, Steidl C, Krieger O, Stauder R, Giagounidis AA, Strupp C, Kundgen A, Mueller T, Haas R, Gattermann N, Aul C.: Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)
    Leukemia 2005 Dec;19(12):2223-31
    Subjects: MDS
  6. Germing U,Strupp C,Kuendgen A,Isa S,Knipp S,Hildebrandt B,Giagounidis A,Aul C,Gattermann N,Haas R: Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.
    Haematologica 2006 Dec;91(12):1596-604 [pmid:17145595]
    Subjects: MDS
  7. Germing U,Strupp C,Kuendgen A,Aivado M,Giagounidis A,Hildebrandt B,Aul C,Haas R,Gattermann N: Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals.
    British journal of haematology 2006 Jan;132(2):162-7 [pmid:16398650]
    Subjects: MDS
  8. Giagounidis AA, Haase S, Germing U, Schlegelberger B, Wilkens L, Busche G, Kreipe HH, Wysk J, Grips KH, Grabenhorst U, Rothmann F, Lubbert M, Ganser A, Aivado M, Heinsch M, Aul C.: Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study.
    Ann Hematol 2005 Jun;84(6):389-94
    Subjects: MDS
  9. Hellstrom-Lindberg E.: Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents
    Hematology (Am Soc Hematol Educ Program) 2005;:161-6
    Subjects: MDS
  10. Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E.: Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF
    Blood 2005 Aug 1;106(3):803-11
    Subjects: MDS
  11. Kroger N, Brand R, van Biezen A, Bron D, Blaise D, Hellstrom-Lindberg E, Gahrton G, Powles R, Littlewood T, Chapuis B, Zander A, Koza V, Niederwieser D, de Witte T: Myelodysplastic Syndromes Subcommittee of the Chronic Leukaemia Working Party, European Blood and Marrow Transplantation Group. Stem cell transplantation from identical twins in patients with myelodysplastic syndromes
    Bone Marrow Transplant 2005 Jan;35(1):37-43
    Subjects: MDS
  12. Kroger N, Brand R, van Biezen A, Cahn JY, Slavin S, Blaise D, Sierra J, Zander A, Niederwieser D, de Witte T.: Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome
    Bone Marrow Transplant 2005 Nov 21
    Subjects: MDS
  13. Lindberg EH.: Strategies for biology- and molecular-based treatment of myelodysplastic syndromes
    Curr Drug Targets 2005 Sep;6(6):713-25
    Subjects: MDS
  14. Loh ML, Martinelli S, Cordeddu V, Reynolds MG, Vattikuti S, Lee CM, Wulfert M, Germing U, Haas P, Niemeyer C, Beran ME, Strom S, Lubbert M, Sorcini M, Estey EH, Gattermann N, Tartaglia M.: Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia
    Leuk Res 2005 Apr;29(4):459-62 [pmid:0015725481]
    Subjects: MDS
  15. Malcovati L, Della Porta MG, Lunghi M, Pascutto C, Vanelli L, Travaglino E, Maffioli M, Bernasconi P, Lazzarino M, Invernizzi R, Cazzola M.: Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome
    Leukemia 2005 May;19(5):776-83 [pmid:0015789068]
    Subjects: MDS
  16. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino M, Cazzola M.: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making
    J Clin Oncol 2005 Oct 20;23(30):7594-603 [pmid:0016186598]
    Subjects: MDS
  17. Pitako JA, Haas PS, Van den Bosch J, Muller-Berndorff H, Kundgen A, Germing U, Wijermans PW, Lubbert M.: Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine
    Ann Hematol 2005 Dec;84 Suppl 13:25-31
    Subjects: MDS
  18. Sanz MA, Fenaux P, Lo Coco F: European APL Group of Experts. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence
    Haematologica 2005 Sep;90(9):1231-5 [pmid:16154847]
    Subjects: MDS
  19. Schmelz K, Sattler N, Wagner M, Lubbert M, Dorken B, Tamm I.: Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms
    Leukemia 2005 Jan;19(1):103-11
    Subjects: MDS
  20. Strupp C,Gattermann N,Giagounidis A,Aul C,Hildebrandt B,Haas R,Germing U: Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals.
    Leukemia research 2003 May;27(5):397-404 [pmid:12620291]
    Subjects: MDS
  21. Zwierzina H, Suciu S, Loeffler-Ragg J, Neuwirtova R, Fenaux P, Beksac M, Harousseau J, Nuessler V, Cermak J, Solbu G, Willemze R, de Witte T, Amadori S: EORTC Leukemia Cooperative Group. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group
    Leukemia 2005 Nov;19(11):1929-33
    Subjects: MDS

Printing Date: 21.11.2008   ©  2004-2008 ELIC European Leukemia Information Center